ライフサイエンスコーパス: ECP

1 ECP after 19-d courses (n = 2,262) was lower in older ch

2 ECP and EDN each induced distinct skin lesions at >or=2.

3 ECP and EDN localized to dermal cells within 2 days, whe

4 ECP bound to oligosaccharides of at least arabinotriose

5 ECP is a pilus of EHEC O157:H7 with a potential role in

6 ECP is now under investigation for use in patients with

7 ECP is thought to control these diseases in part through

8 ECP levels were >200 ng/ml in 61% of persons with colds

9 ECP plays a dual role in early-stage biofilm development

10 ECP primes IL-1beta production and activates IL-1beta ma

11 ECP production was demonstrated in 121 (71.6%) of a tota

12 ECP release was measured by radioimmunoassay.

13 ECP was generally well tolerated.

14 ECP was initiated approximately 2 years after onset of c

15 ECP-1 monomeric units were also shown to assemble into h

16 ECP-treated autologous splenocytes resulted in immune to

17 ECPs facilitate U1 association with RNAs with weak 5' SS

18 tely 52% identity to the egg case protein 1 (ECP-1) fibroin-like family member.

19 Relative to ECP-1, ECP-2 mRNA levels were determined to be >2-fold higher.

20 g-2, VEGF, TGF-beta1, Cys-LTs, MMP-2, IL-13, ECP, and IL-8 measurement in supernatants.

21 e have named this factor egg case protein 2 (ECP-2).

22 For both RNase A(ECP) and H48A there is a 10-fold decrease in the product

23 of the product analogue, 3'-CMP, to RNase A(ECP) results in only minor chemical shift changes in the

24 The chimera (RNase A(ECP)) experiences only local perturbations in NMR backbo

25 of the true uncomplexed ECP32-cleaved actin (ECP-actin) solved to 1.9 A resolution is reported.

26 Appropriately modified by future advances, ECP may potentially offer a general source of therapeuti

27 aGVHD achieved complete remission (CR) after ECP.

28 Immunologic effects observed after ECP included normalization of inverted ratios of CD4 to

29 id refractory cGHVD achieved CR and PR after ECP, respectively.

30 to Th2 (IL-4, IL-10) cytokine profile after ECP, and 8 of 10 had a clinical response to ECP.

31 ng the mechanism leading to a response after ECP.

32 centrates and peripheral blood samples after ECP.

33 An ECP mutant showed only a modest reduction in adherence t

34 MATERIALS AND We analyzed ECP and histamine production in response to LPS by ELISA

35 Alignments of ECP-1 and ECP-2 demonstrate highly conserved N termini, with 16 Cy

36 e fiber, our findings suggest that ECP-1 and ECP-2 play important structural roles in the egg case si

37 stinctive protein architectures of ECP-1 and ECP-2, along with their co-localization with TuSp1 in th

38 ng tubuliform spidroin 1 (TuSp1), ECP-1, and ECP-2.

39 and inflammatory features (IL-12, IL-13 and ECP).

40 ntrations were associated with high IL-5 and ECP protein levels.

41 Levels of IL-6 and ECP did not change significantly during the study.

42 While RNase 7 and ECP/RNase 3 are both cationic and share this particular

43 pression patterns, suggests that RNase 7 and ECP/RNase 3 may have been recruited to target different

44 The correlation between MIP-1-alpha and ECP concentrations suggests a role for eosinophil degran

45 CRSsNP and CRSwNP, identifying S aureus and ECP as novel and crucial players in this process.

46 sess the effect of Staphylococcus aureus and ECP on sRAGE processing.

47 xpression of the Histidine decarboxylase and ECP by flow cytometry and fluorescence microscopy in neu

48 higher levels of histidine decarboxylase and ECP than those from healthy volunteers, and they also re

49 ve to spotlight the unique nature of EDN and ECP and the unusual evolutionary constraints to which th

50 use genes identified as orthologs of EDN and ECP form a highly divergent, species-limited cluster.

51 cigranulocytic, whereas as expected FeNO and ECP were higher in eosinophilic and mixed asthma, while

52 was demonstrated with an ecpR-GFP fusion and ECP antibodies.

53 ge of neutrophils as source of histamine and ECP in the progression of the periodontitis disease.

54 Leukotriene and ECP levels were measured using EIAs or ELISAs.

55 Sputum cys-LT and ECP were a mean (95% CI) 1.6-fold (1.1, 2.5) and 6.4-fol

56 he human eosinophil granule proteins MBP and ECP affect human corneal epithelial cell viability and m

57 Cells treated with MBP and ECP induced a dose-dependent gradual increase in morphol

58 At 24 hours, both MBP and ECP induced statistically significant (P < 0.05) decreas

59 aqueous shunt to extraocular reservoir, and ECP.

60 and functional ortholog of primate EDNs and ECPs.

61 Better communication between PCPs and ECPs, further implementation of EMRs, and increasing eye

62 cells, and the binding was blocked with anti-ECP antibodies, confirming that the pili possess adhesin

63 Because ECP induces normal monocytes to enter the DC differentia

64 vestigated, attempts to make saturated black ECPs have not been reported, probably owing to the compl

65 f P. aeruginosa to silicon was controlled by ECP, in addition to LPS.

66 suggesting that they were also influenced by ECP, especially polysaccharides.

67 Of interest, IL-1beta maturation by ECP was fully intact in murine cells deficient in caspas

68 induction of immunostimulatory mediators by ECP.

69 ence for promotion of IL-1beta production by ECP and offer new insight into the immunostimulatory cap

70 The induction of this tolerant state by ECP was obviated by cotreatment with lipopolysaccharide,

71 tometry in 32 patients with cGvHD treated by ECP for a minimum of 3 months, and up to 12 months.

72 the hypothesis that in patients with cGVHD, ECP modulates alloreactivity by affecting activated lymp

73 In conclusion, ECP and EDN disrupt skin integrity and cause inflammatio

74 I 69.7%-79.7%); among 159 inpatient courses, ECP was 47.7% (95% CI 39.7%-57.3%).

75 opic and transscleral cyclophotocoagulation (ECP, TCP) are generally reserved for refractory glaucoma

76 number of endoscopic cyclophotocoagulations (ECPs) increased 99% from 5383 to 10 728.

77 ossmatch tests performed using donor-derived ECPs allow for the identification of alloantibodies that

78 duction and potential stability, the p-doped ECPs with low oxidation potentials such as PPy need to b

79 suggests that early BAFF measurement during ECP for cGVHD represents a potentially useful biomarker

80 nety-five patients were randomized to either ECP and standard therapy (n = 48) or standard therapy al

81 vidence demonstrating that the gene encoding ECP is regulated in an analogous fashion and that an int

82 In addition to cys-LTs, LL-37 enhances ECP release from eosinophils via pERK1/2.

83 also derive a structural model for entwined ECP fibers that not only illuminates interbacteria commu

84 FeNO, ECP and IL-8 were all low in the paucigranulocytic, wher

85 tricted patterns of expression for fibroins, ECP-1 was demonstrated to be predominantly produced in t

86 r lysine-aspirin challenge were analyzed for ECP, tryptase, PGE2 , PGD2 , LTD4 , and LTE4 .

87 Spinach was found to be enriched for ECP/LM13 targets compared with lettuce.

88 e of an inflammasome-independent pathway for ECP-dependent IL-1beta maturation.

89 s the best E(0) reproducibility reported for ECP-based SCISEs.

90 These data suggest an important role for ECP in the biology of ETEC, particularly in CF-negative

91 receiving better communication/feedback from ECPs, (3) having ophthalmologists hold clinic days in pr

92 of other eosinophil granule proteins (e.g., ECP and EDN), which often detect the presence of these p

93 lasmid present in nonadherent E. coli HB101, ECP rendered this organism highly adherent at levels com

94 Low haemoglobin was associated with higher ECP.

95 eresis (ECP) is thought to contribute to how ECP exerts its therapeutic effect in patients with chron

96 there has been progress in understanding how ECP works at the cellular level.

97 The crystal structure of human ECP, determined at 2.4 A, is similar to that of RNase A

98 emical characterization of recombinant human ECP (rhECP) prepared in baculovirus, and demonstrate tha

99 s noted accompanied by minimal elevations in ECP and albumin.

100 number of 34+DR- cells and LTC-IC present in ECP CML marrow was similar to that in normal (NL) marrow

101 e developed a novel method for incorporating ECP treatment into well-established and clinically relev

102 90 both caused inhibition of eotaxin-induced ECP release and chemotaxis.

103 Of particular interest, ECP/RNase 3's cationicity is based on an (over)abundance

104 Hence, MBP, ECP, and EPO perturb the corneal epithelium differential

105 Overall mean ECP was 74.5% (95% CI 69.7%-79.7%); among 159 inpatient

106 High BAFF at 1-month ECP associated with a worsening median 6-month skin scor

107 RAST), nasal eosinophilia, or elevated nasal ECP (odds ratios = 17, 21, and 25, respectively).

108 NSAID-UA subjects showed no changes in nasal ECP, whereas subjects with AERD had increased levels of

109 scribed here is N-glycosylated, as is native ECP, and has approximately 100-fold more ribonuclease ac

110 thermore, 34+DR- cells from more than 80% of ECP CML patients were BCR/ABL mRNA- and Ph-negative and

111 cellular localization and RNase activity of ECP and EDN were critical for lesion formation; differen

112 te specificity and low catalytic activity of ECP.

113 Alignments of ECP-1 and ECP-2 demonstrate highly conserved N termini,

114 , eosinophils released significant amount of ECP when cultured with RSV-infected A549 cells.

115 ight into the biogenesis and architecture of ECP.

116 ith the distinctive protein architectures of ECP-1 and ECP-2, along with their co-localization with T

117 sight into the immunostimulatory capacity of ECP.

118 5%-95%; P < or =.002) after a 2-day cycle of ECP and longitudinally over the 12-month course of thera

119 ess, evidence for considerable divergence of ECP is also implicit in the structure.

120 To further elucidate the effects of ECP on activated lymphocyte subpopulations and the inter

121 vealed a significant improvement in favor of ECP (P < .001).

122 produced the novel anti-pathogen function of ECP.

123 lls in all patients before the initiation of ECP.

124 s subjects with AERD had increased levels of ECP, with the highest peak at 15 min after challenge (P

125 -chromosome inactivation) in the majority of ECP CML patients, before and after mobilization and irre

126 BAFF level at 1 month of ECP predicted 3- and 6-month skin disease response, with

127 estigated the distribution and production of ECP among a collection of 136 human CF-positive and CF-n

128 pression of ICAM-1 on A549 cells, release of ECP was inhibited significantly by anti-CD18 mAb, but no

129 tein data base using the primary sequence of ECP-1 revealed similarity to fibroins from spiders and s

130 be identified within the primary sequence of ECP-1.

131 oorly represented in the primary sequence of ECP-2, but scattered blocks of polyalanine were present,

132 At the time of ECP, 22 (49%) and 23 (51%) of 45 patients with aGHVD wer

133 We demonstrate that the use of ECP as a prophylaxis prior to conditioning significantly

134 findings fed into an Expert Consensus Panel (ECP) Delphi approach to establish consensus regarding tr

135 irway secretions from RSV-infected patients; ECP concentrations correlated with MIP-1-alpha concentra

136 6 evaluable patients in early chronic phase (ECP), a major cytogenetic response with interferon-based

137 now present data on 27 early chronic-phase ([ECP] studied within 1 year after diagnosis) and 23 advan

138 e time of mobilization (early chronic phase [ECP] > late CP > accelerated phase).

139 Extracorporeal photochemotherapy (ECP) has been associated with clinical improvement in se

140 Extracorporeal photochemotherapy (ECP) has been shown to be an effective therapy for patie

141 Extracorporeal photochemotherapy (ECP) is widely used to treat cutaneous T-cell lymphoma,

142 nd efficacy of extracorporeal photopheresis (ECP) for 12 to 24 weeks together with standard therapy w

143 Extracorporeal photopheresis (ECP) is a widely used clinical cell-based therapy exhibi

144 Extracorporeal photopheresis (ECP) is an important therapeutic option in steroid-refra

145 Extracorporeal photopheresis (ECP) is considered a valid second-line treatment for acu

146 g) cells after extracorporeal photopheresis (ECP) is thought to contribute to how ECP exerts its ther

147 Extracorporeal photopheresis (ECP), a technique that exposes isolated white blood cell

148 Extracorporeal photopheresis (ECP), an immunomodulating procedure that treats pheresed

149 ) treated with extracorporeal photopheresis (ECP).

150 be induced by extracorporeal photopheresis (ECP).

151 The Escherichia coli common pilus (ECP) is produced by commensal and pathogenic E. coli str

152 The Escherichia coli common pilus (ECP) represents a remarkable family of extracellular fib

153 the recently described E. coli common pilus (ECP) to the overall adherence properties of EPEC.

154 factor, herein called E. coli common pilus (ECP), composed of a 21-kDa pilin subunit whose amino aci

155 geted for adherence by E. coli common pilus (ECP; or meningitis-associated and temperature-regulated

156 electrochemically active conducting polymer (ECP) coating the working electrode of an electrochemical

157 accharides (LPS) and extracellular polymers (ECP) on the adhesion of Pseudomonas aeruginosa PAO1 (exp

158 Electrically conducting polymers (ECPs) are one of the most popular types of materials to

159 most recently green electrochromic polymers (ECPs) required for additive primary colour space were in

160 d absolute counts of Treg cells changed post-ECP, and examined correlation with response.

161 among cGvHD patients, and the increase post-ECP was not significant until 6 months.

162 higher median Treg cell counts 3 months post-ECP than nonresponders, as did steroid responders at 56

163 or Treg cells at baseline to 12 months post-ECP were compared with changes in skin disease scores or

164 hanges in CD4+ % at 6, 9, and 12 months post-ECP.

165 sponders at 56 weeks who were 12 months post-ECP.

166 g donor-derived endothelial cell precursors (ECPs) and kidney allograft rejection and function.

167 en randomly showed that 58% of them produced ECP independently of the presence or absence of CFs, a p

168 The use of prophylactic ECP may provide an alternative and safe method for immun

169 We injected eosinophil cationic protein (ECP or RNase 3), eosinophil-derived neurotoxin (EDN or R

170 es and (ii) the eosinophil cationic protein (ECP) and eosinophil-derived neurotoxin (EDN) genes.

171 The genes for eosinophil cationic protein (ECP) and eosinophil-derived neurotoxin (EDN) in primates

172 Eosinophil cationic protein (ECP) and eosinophil-derived neurotoxin (EDN), the eosino

173 toxin (EDN) and eosinophil cationic protein (ECP) are both small, cationic ribonuclease toxins that a

174 immunoassay, eosinophilic cationic protein (ECP) by fluoroimmunoassay, prostanoids (PGE(2), PGD(2),

175 hil numbers and eosinophil cationic protein (ECP) in both nasal washes and serum, along with total Ig

176 ctoferrin and eosinophilic cationic protein (ECP) in nasal secretions.

177 ncentrations of eosinophil cationic protein (ECP) in the asthmatic group (p = 0.08).

178 Eosinophil cationic protein (ECP) is located in the matrix of the eosinophil's large

179 Eosinophil cationic protein (ECP) is one of two RNase A-superfamily ribonucleases fou

180 eotaxin-induced eosinophil cationic protein (ECP) release and chemotaxis.

181 ociation with eosinophilic cationic protein (ECP) was detected by fluorescence staining techniques an

182 -8, IL-13 and eosinophilic cationic protein (ECP) were also measured in sputum supernatant.

183 RAGE, IL-5, and eosinophil cationic protein (ECP) were quantitatively assessed in inflamed tissue of

184 ncentrations of eosinophil cationic protein (ECP), a cytotoxic protein contained in the granules of e

185 and 8 (IL-8), eosinophilic cationic protein (ECP), and myeloperoxidase (MPO) as markers of response t

186 ifferentials, eosinophilic cationic protein (ECP), and tryptase were evaluated.

187 eukotrienes and eosinophil cationic protein (ECP), are well-known mediators of inflammation and tissu

188 protein (MBP), eosinophil cationic protein (ECP), eosinophil peroxidase (EPO), and eosinophil-derive

189 as the human eosinophilic cationic protein (ECP), from intracellular granules is central to the role

190 se A homologue, eosinophil cationic protein (ECP), replaced the 12-residue loop 1 in RNase A.

191 h SCORAD score, eosinophil cationic protein (ECP), total IgE, IL-4, IL-13 and IL-31 in children with

192 toxin (EDN) and eosinophil cationic protein (ECP), which have incorporated nonsilent mutations at ver

193 toxin (EDN) and eosinophil cationic protein (ECP).

194 phil counts and eosinophil cationic protein (ECP)] induced by bronchial instillation of house dust mi

195 N, RNase 2) and eosinophil cationic protein (ECP, RNase 3), from >50 human individuals.

196 DN/RNase 2) and eosinophil cationic protein (ECP/RNase 3), are among the most rapidly evolving coding

197 cationic RNase, eosinophil cationic protein (ECP/RNase 3, pI 11.4).

198 ognition of the BS by the E complex protein (ECP) branchpoint bridging protein (BBP).

199 degranulation (eosinophil cationic protein [ECP] in BAL fluid) and lung injury, which largely resolv

200 poor communication from eye care providers (ECPs), (2) patients' lack of finances/insurance coverage

201 Purified ECP bound in a dose-dependent manner to epithelial cells

202 factor (BAFF) in 46 cGVHD patients receiving ECP before and during treatment course.

203 lines in the United Kingdom that recommended ECP for patients with advanced CTCL, particularly after

204 nd thus of the two eosinophil ribonucleases, ECP and eosinophil-derived neurotoxin (EDN)] remains con

205 BDNF correlated with disease activity, serum ECP, and total IgE serum levels in AD.

206 s with the hypereosinophilic syndrome showed ECP and EDN deposition comparable to that in guinea pig

207 be selected from steady-state marrow in some ECP CML patients, we determined if similar results could

208 No significant change in sputum ECP and tryptase was observed between rPAF-AH and placeb

209 The CR rate in patients who started ECP being nonresponsive and in PR after steroid was 86%

210 survival was seen among patients who started ECP in PR after steroid (80% vs 50% at 2 years; P = 0.07

211 We found that ECP and BFP structures can be simultaneously observed in

212 Our data indicate that ECP is an accessory factor that, in association with BFP

213 We infer that ECP is effective even in patients with extensive cutaneo

214 This study reveals that ECP induces a high percentage of processed monocytes to

215 In this article, we show that ECP promotes marked release of the prototypic immunostim

216 iption quantitative PCR analysis showed that ECP-2 is predominantly expressed in the tubuliform gland

217 Our results suggest that ECP alters alloreactivity by affecting allo-targeted eff

218 These results suggest that ECP may have a steroid-sparing effect in the treatment o

219 The results suggest that ECP modulates both NK cells and APC populations in patie

220 Our data suggest that ECP production is a common feature of E. coli colonizing

221 in the core fiber, our findings suggest that ECP-1 and ECP-2 play important structural roles in the e

222 genic mutant strains tested, suggesting that ECP plays a synergistic role in adherence.

223 The ECP agreed that training in nontechnical skill assessmen

224 The ECP reached consensus regarding who should be targeted t

225 ong to the ribonuclease gene family, and the ECP gene, whose product has an anti-pathogen function no

226 the reporter gene activity supported by the ECP promoter/exon 1/intron construct.

227 rovement in TSS at week 12 was 14.5% for the ECP arm and 8.5% for the control arm (P = .48).

228 than that of synonymous substitution for the ECP gene.

229 ecrease from baseline in TSS was 8.3% in the ECP arm at week 12 and 0% in the control arm (P = .04).

230 The NFAT-1 consensus site in the ECP gene differs from that found in the EDN gene by a si

231 doping ion by which the oxidized form of the ECP becomes hydrophobic.

232 rated in the early stage of evolution of the ECP gene.

233 sidues are distributed on the surface of the ECP molecule that may have implications for an understan

234 This article reviews the evolution of the ECP technique--for example, the most recent generation o

235 st to the much more open conformation of the ECP-actin's nucleotide binding cleft in solution, the cr

236 Principal component analysis of the ECP-induced monocyte transcriptome reveals that activati

237 The forward primer is attached to the ECP.

238 ch mapped to two distinct regions within the ECP-1.

239 The first criterion requires that the ECPs are in their oxidized state, but the high charge de

240 e distinctive molecular signature, common to ECP-processed monocytes from normal subjects, and those

241 ned to erlotinib alone (arm A; n = 81) or to ECP (arm B; n = 100).

242 Relative to ECP-1, ECP-2 mRNA levels were determined to be >2-fold h

243 We reported that clinical response to ECP was associated not only with normalization of skewed

244 parameters predicted a favorable response to ECP, so patient selection must continue to be made on cl

245 ECP, and 8 of 10 had a clinical response to ECP.

246 ited in 6 Italian centers, were submitted to ECP for second-line treatment.

247 on of both AECAs and HLA antibodies bound to ECPs was performed using flow cytometry.

248 Processable black-to-transmissive ECPs promise to affect the development of both reflectiv

249 lation, were equally effective in triggering ECP release if they were cultured with eosinophils in th

250 e, containing tubuliform spidroin 1 (TuSp1), ECP-1, and ECP-2.

251 These lesions were ulcerated (ECP) or crusted (EDN) with marked cellular infiltration.

252 lution, the crystal structure of uncomplexed ECP-actin contains actin in a typical closed conformatio

253 s from patients with chronic GVHD undergoing ECP therapy.

254 rse VBLL as a percentage of pre-course VBLL (ECP).

255 of additional subtypes of glaucoma, whereas ECP and TCP are generally reserved for refractory glauco

256 is rarely found in other organisms, whereas ECP is widespread in E. coli and other environmental ent

257 The efficiency with which ECP stimulates new functional DCs supports the possibili

258 the release of sRAGE from the tissue, while ECP was shown to be implicated in the breakdown of free

259 ing of mitochondrial DNA in association with ECP in a concentration- and time-dependent manner.

260 the relative associations of covariates with ECP.

261 In patients with ECP CML, mobilized PB collections yielded significantly

262 rate that the transfer of cells treated with ECP reverses established GVHD by increasing donor regula

263 s who had refractory cGVHD were treated with ECP, and the clinical response to and immunologic effect

264 oxicity was greater in patients treated with ECP.